01530 3SBIO
- 6.080
- +0.030+0.50%
3SBIO News
Sansheng Pharmaceutical (01530.HK): Zhang Dan intends to retire as an independent non-executive director
Gelonghui, April 22 | Sansheng Pharmaceutical (01530.HK) announced that Zhang Dan, an independent non-executive director, will step down in rotation at the company's annual general meeting of shareholders to be held on June 25, 2024. Independent non-executive director Wong Cho-yiu has been appointed by the board of directors as a member of the Remuneration Committee, effective immediately after the 2023 Annual General Meeting of Shareholders to be held on June 25, 2024.
Sansheng Pharmaceutical (01530): Wong Cho-yiu appointed as a member of the Remuneration Committee
Sansheng Pharmaceutical (01530) issued an announcement. According to the company's articles of association, Zhang Dan, an independent non-executive director, will...
Sansheng Pharmaceutical (01530.HK) spent HK$838,900 to buy back 150,000 shares on April 22
Gelonghui, April 22丨Sansheng Pharmaceutical (01530.HK) announced that it spent HK$838,900 to repurchase 150,000 shares on April 22.
Sansheng Pharmaceutical (01530.HK) spent HK$20.315 million to buy back 3.537 million shares on April 16
Gelonghui announced on April 16: Sansheng Pharmaceutical (01530.HK) announced that it spent HK$20.315 million to repurchase 3,537 million shares on April 16.
Is 3SBio (HKG:1530) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Sansheng Pharmaceutical (01530.HK) spent HK$15.598 million to repurchase 2,649,500 shares on April 15
Gelonghui, April 15 | Sansheng Pharmaceutical (01530.HK) announced that it spent HK$15.598 million to repurchase 2,649,500 shares on April 15.
3SBIO Gets China Nod for Use of Cancer Injection in Children With Thrombocytopenia
3SBIO (HKG:1530) said the National Medical Products Administration of China approved its Recombinant Human Thrombopoietin Injection for the treatment of persistent or chronic primary immune thrombocyt
Sansheng Pharmaceutical (01530.HK) Recombinant Human Thrombocytopoietin Injection (Terbiao) Approved for ITP Indications for Children
Gelonghui, April 12, 丨 Sansheng Pharmaceutical (01530.HK) announced that the new indications for Sansheng Pharmaceutical's recombinant human thrombocytopenia injection (Terbiao) submitted by the company to the National Drug Administration (NMPA) were approved on April 2 to treat persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. Terbiao is a recombinant human thrombopoietin (rHTPO) injection independently developed by Sansheng Pharmaceutical. It has previously been approved for adult solid tumors after chemotherapy
Sansheng Pharmaceutical (01530) spent HK$10.3888 million to buy back 1.746 million shares on April 12
Sansheng Pharmaceutical (01530) announced that on April 12, 2024, the company spent 10.3888 million...
Sansheng Pharmaceutical (01530) spent HK$16.7497 million to buy back 2.805 million shares on April 11
According to the Zhitong Finance App, Sansheng Pharmaceutical (01530) announced that on April 11, 2024, the company spent HK$16.7497 million to repurchase 2,805 million shares at a repurchase price of HK$5.92-6.04 per share.
[Broker Focus] Northeast Securities maintains Sansheng Pharmaceutical's (01530) “buy” rating, indicating that the company's product system is mature and optimistic about long-term development
Jinwu Financial News | According to the Northeast Securities Research Report, recently, Sansheng Pharmaceutical (01530) announced its 2023 annual results. The company's revenue was $7.816 billion (+13.8% YoY), adjusted operating net profit of $1,952 million (YoY +17.7%), R&D expenses of $795 million (YoY +14.55%), sales and marketing expenses of $3.06 billion (YoY +16.50%), and paid a 2023 dividend of HK$0.25 per share, corresponding dividend rate of approximately 4.5%. The company announcement was approved to buy back up to 2.44 on the Stock Exchange of Hong Kong Limited
Sansheng Pharmaceutical (01530.HK) spent HK$6.61 million to buy back 1.08 million shares on April 10
Gelonghui, April 10 | Sansheng Pharmaceutical (01530.HK) announced that it spent HK$6.61 million to buy back 1.08 million shares on April 10.
Sansheng Pharmaceutical (01530.HK) spent HK$4.313,400 to buy back 721,500 shares on April 8
Gelonghui, April 8, 丨 Sansheng Pharmaceutical (01530.HK) announced that it spent HK$4.313,400 to buy back 721,500 shares on April 8.
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
Sansheng Pharmaceutical (01530.HK) spent HK$3.6516 million to buy back 600,000 shares on April 3
Gelonghui announced on April 3: Sansheng Pharmaceutical (01530.HK) announced that it spent HK$3.6516 million to repurchase 600,000 shares on April 3.
Sansheng Pharmaceutical (01530.HK) spent HK$7.049 million to buy back 1.164,500 shares on April 2
Gelonghui, April 2 | Sansheng Pharmaceutical (01530.HK) announced that it spent HK$7.049 million to buy back 1.164,500 shares on April 2.
Sansheng Pharmaceutical (01530.HK) spent HK$6.012 million to buy back 1 million shares on March 28
On March 28, Gelonghui Pharmaceutical (01530.HK) announced that it spent HK$6.012 million to buy back 1 million shares on March 28.
Sansheng Pharmaceutical (01530.HK) spent HK$5.744 million to buy back 1 million shares on March 27
On March 27, Gelonghui | Sansheng Pharmaceutical (01530.HK) issued an announcement. On March 27, 2024, it spent HK$5.744 million to repurchase 1 million shares at a repurchase price of HK$5.72-5.75 per share.
Sansheng Pharmaceutical (1530.HK): High performance growth, Davis double hit potential stocks
Recently, a secret document from the General Office of the National Development and Reform Commission called the “Draft for Solicitation of Comments on the Implementation Plan to Support the Development of Innovative Drugs in the Whole Chain” made waves in the market. The document elevates the development of innovative drugs to the level of a national strategy. It sees it as the key to promoting new quality productivity and seizing the high ground of the pharmaceutical industry, and is closely linked to the country's innovation-driven development, manufacturing power, and healthy China. It not only highlights the importance the government attaches to pharmaceutical innovation, but also marks the establishment of the bottom of pharmaceutical industry policy. At the same time, changes in the external macroeconomic environment have also brought new opportunities to the pharmaceutical sector. With the possibility of a cycle of interest rate cuts, long-term
[Hong Kong Stock Connect] Sansheng Pharmaceutical (01530) rebounded the market and rose 8.84%, and many institutions indicated that its performance was in line with expectations
Jinwu Financial News | Sansheng Pharmaceutical (01530) rebounded higher. As of press release, it reported HK$5.91, up 8.84%, with a turnover of HK$140 million. According to the news, Lyon published a report saying that Sansheng Pharmaceuticals's revenue last year was in line with expectations, but profits were 24.5% lower than the bank's expectations, mainly because sales and promotion expenses were higher than expected. Since pipeline products in preparation will only be launched after 2025, it is estimated that this year will be a relatively quiet year for the company. In response to the company's positive action to increase shareholder returns, the target price was raised from HK$5.7 to HK$6.2, reflecting a projected price-earnings ratio of 6.5 times, maintaining a “run”
Analysis
Price Target
No Data
